Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

IDEA Collider: Innovation & Asymmetric Learning in Pharma

IDEA Collider: Innovation & Asymmetric Learning in Pharma artwork

Targeting the Totality of MS: Jason Tardio on Immunic’s Combined Neuroprotective and Anti-Inflammatory Strategy

Jul 16, 202649 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of Multiple Sclerosis (MS) treatment. For 30 years, MS therapies have primarily focused on controlling inflammation and visible relapses. Jason argues it’s time to look deeper and address the ongoing neurodegeneration driving long-term disability, known as Progression Independent of Relapse Activity (PIRA). We explore Immunic's investigational therapy, vidofludimus calcium, and its unique dual-mechanism approach: acting as a DHODH inhibitor for anti-inflammatory benefits while also activating the Nurr1 nuclear receptor to potentially provide direct neuroprotection. Jason shares insights from the EMPHASIS and CALIBER clinical trials, discusses why the industry needs safer immunomodulators rather than just broad immunosuppressants (especially as the MS population ages), and shares a fascinating biological link between MS remission during pregnancy and Nurr1 levels. Tune in to hear what the next 10 to 15 years hold for MS patients, including the ultimate goals of halting progression entirely and achieving remyelination. Episode Timestamps 00:00:00 - Introduction: Meet Jason Tardio, President and COO of Immunic. 00:02:01 - The Evolution of MS Treatment: Transitioning from purely anti-inflammatory approaches to addressing underlying neurodegeneration. 00:04:29 - What is PIRA?: Understanding Progression Independent of Relapse Activity and why patients still accumulate disability. 00:10:30 - The Dual-Mechanism Approach: How vidofludimus calcium combines DHODH inhibition with Nurr1 activation. 00:13:33 - The Power of Nurr1: Exploring the target's role in neuronal survival and the fascinating biological link to pregnancy in MS patients. 00:18:14 - Clinical Validation: Analyzing data from the EMPHASIS (relapsing MS) and CALIBER (progressive MS) trials. 00:27:42 - Standing Out in a Crowded Market: Why safety, tolerability, and avoiding broad immunosuppression matter, especially for aging MS patients facing immunosenescence. 00:36:08 - The Next 10 Years: Moving towards halting progression, potential remyelination, and the need to reclassify MS beyond relapsing and progressive labels. Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Jason Tardio; LinkedIn: https://www.linkedin.com/in/jason-tardio/ Keep up with Rick Ritacco: LinkedIn: https://www.linkedin.com/in/rritacco/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. ESMO 2026 Preview: Key studies that could fundamentally change the oncology landscape.

    Oct 22, 202642 minAudio

    In this episode of the IDEA Collider podcast, Alex Gray, Chief Medical Officer at SAI & IDEA Pharma, John Barry, Executive Vice President at SAI, and Tom Brockbank, Senior Consultant at IDEA Pharma, look ahead to ESMO...

    Credit the people on this episode

  2. AI-Driven Pharma Market Research: Synthetic Users - with Kwame Ferreira & Rebecca Gould.

    Oct 7, 202641 minAudio

    Welcome back to the IDEA Collider podcast. In this episode, host Rick Ritacco sits down with Kwame Ferreira, Founder of Synthetic Users, and Rebecca Gould, President, Strategic Consulting & Analytics Business Unit at...

    Credit the people on this episode

  3. The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution: Part II

    Sep 14, 202636 minAudio

    Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank to discuss what lies ahead for cancer...

    Credit the people on this episode

  4. The Future of Psychedelic Medicine: Clinical Strategy and Scaling Access.

    Jul 1, 202650 minAudio

    Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly...

    Credit the people on this episode

  5. The Power of the Early Narrative: Sue Wood on Strategic Biotech Positioning

    Jun 24, 202643 minAudio

    Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Sue Wood, a senior expert at IDEA Pharma with a PhD from Oxford and decades of experience translating complex scientific concepts...

    Credit the people on this episode